Small Cell Lung Cancer Clinical Trial
Official title:
"EXHALE" A Randomized Clinical Trial Comparing the Effects of a 12 Week Supervised Exercise Intervention Versus Usual Care for Advanced Stage Lung Cancer Patients.
The aim of this study is to evaluate the effect of twelve weeks of a physical and psycho-social program consisting of: supervised, structured exercise training in a group of advanced lung cancer patients (cardio and strength training, relaxation training) twice weekly. Primary outcome is (VO2peak). The hypotheses are that patients who undergo this intervention will increase maximal oxygen uptake (VO2peak), strength (1RM), functional capacity (6MWD) and quality of life (HRQOL) and reduce the level of anxiety and depression compared to those who do not.
Control - usual care The patients randomized to the control group received no training but
are offered the chance to participate in the supervised training after they have completed
their antineoplastic treatment, at least after twelve weeks. Patients in early 2nd line
treatment ("switch maintenance") will be offered training after 12 weeks, although they have
not completed chemotherapy.
Intervention The supervised training was carried out in groups of 12-16 patients and each
session had a duration of 1.5 hours, was administered twice weekly and was supervised by a
research physiotherapist. The training comprised warm up exercises, strength and fitness
training as well as stretching. Warm up exercises consisted of 10 minutes of light,
stationery cycling, adjusted to 60-90% of the patient's maximum HR. Strength training was
carried out using 6 machines (Technogym: Leg press, chest press, lateral machine, leg
extension, abdominal crunch, and lower back). The practical aim of strength training was to
complete 3 series of 5-8 sets, with 70-90% of 1RM. The exercises were specifically selected
to involve the largest possible number of muscle groups in the least number of exercises. To
ensure progression in strength training, each patient was instructed in carrying out the 1RM
test using each of the above-mentioned strength training machines once every second week,
after which their program would be adjusted. Cardiovascular training was carried out as
interval training on stationery bikes. Intensity was equivalent to 85-95% of each patient's
maximum HR and lasted approximately 10-15 minutes. After the training session, 5-10 minutes
were dedicated to stretching the large muscle groups in order to increase agility. Following
each training session, progressive relaxation of 15-20 minutes was performed.
Pre training screening Each Patient was screened by a clinical nurse specialist prior to
participating in each physical training session and before the physiological tests (35). If
one of the following criteria were met, the patient was prohibited from exercising/being
tested on that day: diastolic blood pressure <45 or >95, heart rate (HR) at rest >115/min,
temperature > 38 0C, respiratory rate at rest >30/min, infection requiring treatment, fresh
bleeding, total leucocyte count <1.0 109/L or platelets <50 109/L. Physical tests and HRQOL
evaluation were performed at baseline and after six weeks of training.
Statistical analysis Sample size The applied calculations are performed on 55 patients on the
basis of VO2peak; through six weeks of training 55 patients achieved an increase of 0.85 ml /
kg / min in VO2peak (SD = 2,48). It is assumed that the control group in the current study
will have a reduction of 0.5 ml / kg / min for VO2peak (SD = 2.48). Assumptions for
calculation of patient numbers are as follows: Type 1 error 0.05, type 2 error 0.20, and
success level 1.35, SD 2.48. This leads to a total number of patients of 108 (54 in each
arm). This study expects a drop-out rate of 50% and therefore another 108 patients must be
included, which gives a sample size of 216 patients.
Data entry is carried out in the Open Clinica and analysis will be performed using the
computer program SAS. As regards the choice of the statistical tests applied to data in which
there will be no continuous differences, that will be analyzed by paired t-test or a
corresponding non-parametric test, as categorical data are analyzed using the Pearson χ2
tests. Other data (e.g., from questionnaires) are analyzed using logistic regression and chi
square or Mantel Haenzel test. Significance level is set at 0.05.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT03651219 -
Mesylate Apatinib Combined With Irinotecan in Treatment of Recurrent Small Cell Lung Cancer
|
Phase 3 | |
Active, not recruiting |
NCT03958045 -
Combination Rucaparib With Nivolumab in Small Cell Lung Carcinoma
|
Phase 2 | |
Completed |
NCT04381910 -
Irinotecan Hydrochloride Liposome Injection (LY01610) For Small Cell Lung Cancer
|
Phase 2 | |
Active, not recruiting |
NCT04885998 -
AMG 757 and AMG 404 in Subjects With Small Cell Lung Cancer (SCLC)
|
Phase 1 | |
Active, not recruiting |
NCT03703297 -
Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy
|
Phase 3 | |
Recruiting |
NCT05903092 -
MOnaliZumab in Combination With durvAlumab (MEDI4736) Plus Platinum-based chemotheRapy for First-line Treatment of Extensive Stage Small Cell Lung Cancer
|
Phase 2 | |
Completed |
NCT03652077 -
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies
|
Phase 1 | |
Terminated |
NCT04422210 -
A Study Evaluating The Safety, Tolerability, Pharmacokinetics, And Efficacy Of Venetoclax In Combination With Atezolizumab, Carboplatin, And Etoposide In Participants With Untreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC).
|
Phase 1 | |
Not yet recruiting |
NCT02875457 -
Apatinib as the Maintenance Therapy for Extensive Stage Small Cell Lung Cancer After Combined With Etoposide/Cisplatin
|
Phase 3 | |
Recruiting |
NCT02577627 -
Multi-Indication, Retrospective Oncological Study to Validate the Accuracy in Predicting TTP by PrediCare in Patients Under SOC
|
N/A | |
Recruiting |
NCT02605811 -
Temozolomide in Preventing Brain Metastases in Small Cell Lung Cancer
|
Phase 2 | |
Completed |
NCT02551432 -
Pembrolizumab and Paclitaxel in Refractory Small Cell Lung Cancer
|
Phase 2 | |
Withdrawn |
NCT02542137 -
Abscopal Effect for Metastatic Small Cell Lung Cancer
|
Phase 2 | |
Recruiting |
NCT02262897 -
The Efficacy and Safety of Nab-paclitaxel in Pretreated Patients With Extensive Disease of Small Cell Lung Cancer
|
Phase 2 | |
Completed |
NCT01831089 -
Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors
|
Phase 1 | |
Terminated |
NCT00969306 -
Chloroquine as an Anti-Autophagy Drug in Stage IV Small Cell Lung Cancer (SCLC) Patients
|
Phase 1 | |
Completed |
NCT01943578 -
Value of Physical Capacity Tests in Lung Cancer
|
N/A | |
Completed |
NCT01497873 -
A Randomized Study to Compare the Efficacy and Safety of Belotecan and Topotecan as Monotherapy for Sensitive-Relapsed Small Cell Lung Cancer
|
Phase 2 | |
Terminated |
NCT00958022 -
Carboplatin and Etoposide Plus LBH589 for Small Cell Lung Cancer
|
Phase 1 | |
Completed |
NCT00930891 -
Bevacizumab in Extensive Small Cell Lung Cancer
|
Phase 2/Phase 3 |